{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:39:08Z","timestamp":1782607148167,"version":"3.54.5"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Amgen's novel small-molecule inhibitor AMG 510 has become the first drug to successfully target a KRAS mutation in patients, according to findings presented at the 2019 American Society of Clinical Oncology Annual Meeting. In a phase I trial, AMG 510 elicited partial responses in half of evaluable patients with KRASG12C-mutant non\u2013small cell lung cancer, and led to stable disease in most evaluable patients with colorectal or appendix cancer.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nb2019-073","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T17:55:16Z","timestamp":1560362116000},"page":"988-989","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["AMG 510 First to Inhibit \u201cUndruggable\u201d KRAS"],"prefix":"10.1158","volume":"9","member":"1086","published-online":{"date-parts":[[2019,8,1]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/9\/8\/988\/1840959\/988b.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/9\/8\/988\/1840959\/988b.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T01:56:40Z","timestamp":1654567000000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/9\/8\/988\/41888\/AMG-510-First-to-Inhibit-Undruggable-KRASAMG-510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":0,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2019-073","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}